177 related articles for article (PubMed ID: 38296759)
1. Therapeutic implications of the interplay between interferons and ER in breast cancer.
Todorović-Raković N; Whitfield JR
Cytokine Growth Factor Rev; 2024 Feb; 75():119-125. PubMed ID: 38296759
[TBL] [Abstract][Full Text] [Related]
2. Interferon Signaling in Estrogen Receptor-positive Breast Cancer: A Revitalized Topic.
Fu X; De Angelis C; Schiff R
Endocrinology; 2022 Jan; 163(1):. PubMed ID: 34791151
[TBL] [Abstract][Full Text] [Related]
3. Type I IFN stimulates IFI16-mediated aromatase expression in adipocytes that promotes E
Ka NL; Lim GY; Kim SS; Hwang S; Han J; Lee YH; Lee MO
Cell Mol Life Sci; 2022 May; 79(6):306. PubMed ID: 35593921
[TBL] [Abstract][Full Text] [Related]
4. Prolactin activates Stat1 but does not antagonize Stat1 activation and growth inhibition by type I interferons in human breast cancer cells.
Schaber JD; Fang H; Xu J; Grimley PM; Rui H
Cancer Res; 1998 May; 58(9):1914-9. PubMed ID: 9581833
[TBL] [Abstract][Full Text] [Related]
5. Novel type III interferons produce anti-tumor effects through multiple functions.
Li Q; Kawamura K; Tada Y; Shimada H; Hiroshima K; Tagawa M
Front Biosci (Landmark Ed); 2013 Jun; 18(3):909-18. PubMed ID: 23747856
[TBL] [Abstract][Full Text] [Related]
6. Interferons: role in cancer therapy.
Abdolvahab MH; Darvishi B; Zarei M; Majidzadeh-A K; Farahmand L
Immunotherapy; 2020 Aug; 12(11):833-855. PubMed ID: 32635782
[TBL] [Abstract][Full Text] [Related]
7. The role of interferons in ovarian cancer progression: Hinderer or promoter?
Liu T; Li Y; Wang X; Yang X; Fu Y; Zheng Y; Gong H; He Z
Front Immunol; 2022; 13():1087620. PubMed ID: 36618371
[TBL] [Abstract][Full Text] [Related]
8. Double-edged effects of interferons on the regulation of cancer-immunity cycle.
Zhang X; Wang S; Zhu Y; Zhang M; Zhao Y; Yan Z; Wang Q; Li X
Oncoimmunology; 2021; 10(1):1929005. PubMed ID: 34262796
[TBL] [Abstract][Full Text] [Related]
9. Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus.
Chyuan IT; Tzeng HT; Chen JY
Cells; 2019 Aug; 8(9):. PubMed ID: 31450787
[TBL] [Abstract][Full Text] [Related]
10. Interferons and their stimulated genes in the tumor microenvironment.
Cheon H; Borden EC; Stark GR
Semin Oncol; 2014 Apr; 41(2):156-73. PubMed ID: 24787290
[TBL] [Abstract][Full Text] [Related]
11. IFNs-signaling effects on lung cancer: an up-to-date pathways-specific review.
Galani V; Kastamoulas M; Varouktsi A; Lampri E; Mitselou A; Arvanitis DL
Clin Exp Med; 2017 Aug; 17(3):281-289. PubMed ID: 27416926
[TBL] [Abstract][Full Text] [Related]
12. Importance of Type I and III Interferons at Respiratory and Intestinal Barrier Surfaces.
Stanifer ML; Guo C; Doldan P; Boulant S
Front Immunol; 2020; 11():608645. PubMed ID: 33362795
[TBL] [Abstract][Full Text] [Related]
13. Molecular Changes During Breast Cancer and Mechanisms of Endocrine Therapy Resistance.
Radhi S
Prog Mol Biol Transl Sci; 2016; 144():539-562. PubMed ID: 27865467
[TBL] [Abstract][Full Text] [Related]
14. Induction and regulation of IFNs during viral infections.
Malmgaard L
J Interferon Cytokine Res; 2004 Aug; 24(8):439-54. PubMed ID: 15320958
[TBL] [Abstract][Full Text] [Related]
15. Interferons and progesterone for establishment and maintenance of pregnancy: interactions among novel cell signaling pathways.
Bazer FW; Burghardt RC; Johnson GA; Spencer TE; Wu G
Reprod Biol; 2008 Nov; 8(3):179-211. PubMed ID: 19092983
[TBL] [Abstract][Full Text] [Related]
16. Shared and Distinct Functions of Type I and Type III Interferons.
Lazear HM; Schoggins JW; Diamond MS
Immunity; 2019 Apr; 50(4):907-923. PubMed ID: 30995506
[TBL] [Abstract][Full Text] [Related]
17. Biological and clinical basis for molecular studies of interferons.
Pang KR; Wu JJ; Huang DB; Tyring SK; Baron S
Methods Mol Med; 2005; 116():1-23. PubMed ID: 16007741
[TBL] [Abstract][Full Text] [Related]
18. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
[TBL] [Abstract][Full Text] [Related]
19. Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer.
Haines CN; Wardell SE; McDonnell DP
Essays Biochem; 2021 Dec; 65(6):985-1001. PubMed ID: 34328178
[TBL] [Abstract][Full Text] [Related]
20. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
